XML 37 R22.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Reporting | 3 Months Ended
--- | ---
Mar. 31, 2018
Segment Reporting [Abstract] |
Segment Reporting | ﻿ Note 1 5. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry he alth and to ensure the quality and safety of milk and improve dairy efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements. ﻿ Certain costs are not allocated to our operating segments and are instead reported under the caption “Unallocated Amounts.” These costs include costs that do not align with one of our existing operating segments or are cost prohibitive to allocate, which primarily consist of our R&D function, regional or country expenses, certain foreign currency revaluation gains and losses on monetary balances in currencies other than our subsidiaries’ functional currency and unusual items. Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation are charged to our business segments at pre-determined budgeted amounts or rates. Differences from these pre-determined budgeted amounts or rates are captured within Unallocated Amounts. ﻿ The following is a summary of segment performance for the three months ended March 31, 201 8 and 201 7 (in thousands): ﻿ ﻿ ﻿
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿ |  | For the Three Months Ended March 31, |
﻿ |  |  | CAG |  | Water |  | LPD |  | Other |  | Unallocated Amounts |  | Consolidated Total |
﻿2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿Revenue |  | $ | 470,833 |  | $ | 29,143 |  | $ | 32,240 |  | $ | 5,440 |  | $ | - |  | $ | 537,656 |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿Income (loss) from operations |  | $ | 100,398 |  | $ | 12,462 |  | $ | 2,961 |  | $ | 498 |  | $ | (3,275) |  | $ | 113,044 |
﻿Interest expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (8,695) |
﻿Income before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 104,349 |
﻿Provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,873 |
﻿Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 89,476 |
﻿Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25 |
﻿Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 89,451 |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿Revenue |  | $ | 403,227 |  | $ | 25,077 |  | $ | 29,317 |  | $ | 4,400 |  | $ | - |  | $ | 462,021 |
﻿ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
﻿Income (loss) from operations |  | $ | 79,855 |  | $ | 10,263 |  | $ | 3,802 |  | $ | 393 |  | $ | (2,070) |  | $ | 92,243 |
﻿Interest expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (7,506) |
﻿Income before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 84,737 |
﻿Provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,679 |
﻿Net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 69,058 |
﻿Less: Net income attributable to noncontrolling interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 39 |
﻿Net income attributable to IDEXX Laboratories, Inc. stockholders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 69,019 |
﻿ ﻿ See “Note 3. Revenue Recognition” for a summary of disaggregated revenue by reportable segment and by major product and service category for the three months ended March 31, 2018 and 2017.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration